

GLOBAL SEPSIS ALLIANCE

England & Wales · Charity number 1142803

Details

Other names	GSA
Status	Registered
Legal form	Charitable company
Company number	07476120
Registered	2011-07-08
Register	View on the Charity Commission register

Contact

Address	Rua da Paz 55A Delgada 2540-643 Rolica
Phone	01189701204
Email	phil@ininhs.com
Website	www.global-sepsis-alliance.org

Activities

Objects: TO RELIEVE SICKNESS AND PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF PERSONS SUFFERING FROM SEPSIS BY:(A) THE PROVISION OF FINANCIAL ASSISTANCE, SUPPORT, EDUCATION, RESEARCH AND PRACTICAL ADVICE;(B) INCREASING AWARENESS AND UNDERSTANDING OF SEPSIS AND THE AND ITS TREATMENT AMONGST HEALTH PROFESSIONALS, CORPORATIONS, GOVERNMENTAL AND NON-GOVERNMENTAL ORGANISATIONS AND THE PUBLIC.

Activities: Our Mission Statement: Provide global leadership to reduce the worldwide burden of sepsis

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, Elderly/old People, Other Charities Or Voluntary Bodies, The General Public/mankind

Geography

- Germany
- Reading

Finances

Period end	Income	Expenditure	Assets	Employees
2025-12-31	£365,200	£325,586	-	-
2024-12-31	£119,222	£448,677	-	-
2023-12-31	£322,357	£476,889	-	-
2022-12-31	£254,110	£373,060	-	-
2021-12-31	£343,103	£209,276	-	-
2020-12-31	£267,472	£249,532	-	-

Trustees

Name	Role	Appointed
PROFESSOR KONRAD REINHART	Chair	
PHILIP TAYLOR		
RON DANIELS		2013-11-25

Accounts

REGISTERED COMPANY NUMBER: 07476120 (England and Wales)
REGISTERED CHARITY NUMBER: 1142803

Trustees' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2025
for
Global Sepsis Alliance

RAA Avalon Accounting Ltd
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2025

	Page
Trustees' Report	1 to 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10 to 11
Notes to the Financial Statements	12 to 17
Detailed Statement of Financial Activities	18 to 19

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2025

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research, and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring Our Work Delivers Our Aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees, Board, and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

Review of Activities 2025

During 2025, the Global Sepsis Alliance (GSA) continued to strengthen its role as a global convener, advocate, and knowledge-sharing platform in the fight against sepsis. Through international partnerships, policy engagement, educational activities, and survivor involvement, GSA advanced its mission to reduce preventable sepsis deaths and disabilities worldwide.

The following activities represent the organization's most significant achievements during the year.

Global Advocacy and Policy Engagement

In February, GSA contributed to international policy discussions at the 156th Session of the World Health Organization (WHO) Executive Board in Geneva. GSA called on governments and global health stakeholders to prioritize sepsis within Universal Health Coverage packages and strengthen efforts to prevent, diagnose, and treat sepsis globally.

GSA also published a policy outlook entitled Investing in Sepsis Science for Future Pandemic Preparedness, highlighting the importance of sustained investment in sepsis research as a critical component of global health security.

In March, the European Sepsis Alliance (ESA), coordinated by GSA, held its 8th Annual Meeting at the European Parliament in Brussels, where a Call to Action was launched to encourage European policymakers to develop a coordinated response to sepsis across Europe.

In May, GSA convened the first-ever Official Side Event on Sepsis at the 78th World Health Assembly in Geneva in collaboration with multiple international partners, governments, and global health organizations. During the Assembly, GSA delivered official statements urging WHO Member States to recognize sepsis as a leading cause of preventable death and disability.

In September, GSA organized a side event during the 80th Session of the United Nations General Assembly in New York, further elevating sepsis on the global policy agenda.

Knowledge Sharing and Global Education

The 5th World Sepsis Congress, held in April, represented one of GSA's flagship activities. The free, fully virtual congress brought together almost 12,000 participants from more than 170 countries, with 68% of attendees joining from low- and middle-income countries.

The congress featured expert discussions on sepsis epidemiology, artificial intelligence, antimicrobial stewardship, integrated care pathways, innovations in diagnostics and treatment, and health systems strengthening. Importantly, it also amplified the voices of sepsis survivors and family members.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2025

Throughout the year, GSA expanded its educational offerings through multiple webinars addressing key topics, including antimicrobial stewardship, sepsis management in resource-limited settings, and the intersection between antimicrobial resistance and sepsis.

Survivor and Community Engagement

In April, GSA established the Global Sepsis Survivor Committee (GSSC), creating a formal mechanism for survivors and family members to contribute to GSA's activities and strategic priorities.

Throughout the year, GSA continued to share personal stories from sepsis survivors and families around the world, helping to raise awareness and ensure that lived experiences remained central to advocacy efforts.

In November, GSA launched its Individual Membership Program, enabling survivors, healthcare professionals, researchers, advocates, and members of the public to directly support and participate in the organization's mission.

Strategic Partnerships and Global Collaboration

GSA strengthened existing partnerships and established new collaborations throughout 2025. In March, GSA announced a partnership with the International Fluid Academy to advance education and clinical collaboration in sepsis care.

The organization also continued developing the Global Sepsis Innovations Platform (GSIP), a multi-stakeholder initiative focused on accelerating innovation in sepsis prevention, diagnostics, treatment, and health system implementation.

In February, GSA hosted a symposium in Berlin entitled "Overcoming Silos by Synergizing the Fight Against Sepsis and Antimicrobial Resistance", bringing together experts from multiple disciplines to strengthen collaboration between the global sepsis and antimicrobial resistance communities.

Throughout the year, GSA actively participated in international health forums and maintained engagement with WHO, governments, parliamentarians, healthcare organizations, research institutions, and civil society partners to advance the objectives of the 2030 Global Agenda for Sepsis.

World Sepsis Day

World Sepsis Day in September remained one of GSA's most impactful awareness initiatives. Hundreds of events were organized worldwide by partners and supporters, helping to raise awareness of sepsis among healthcare professionals, policymakers, patients, and the general public.

GSA itself organized three international events, including a central press conference in Berlin and global policy events in Geneva and New York. The campaign also received high-level support from WHO Director-General Dr Tedros Adhanom Ghebreyesus, who delivered a video address to the global sepsis community.

Organizational Development

In June, GSA welcomed its newly elected Board for the 2025-2028 term. Throughout the year, the organization maintained regular engagement with its member organizations, Regional Sepsis Alliances, partners, and sponsors to strengthen governance, coordinate strategic priorities, and build momentum for future initiatives.

Collectively, these activities have further strengthened GSA's position as a leading global organization dedicated to reducing the burden of sepsis through advocacy, education, partnership building, survivor engagement, and policy development.

How Our Activities Deliver Public Benefit

The Global Sepsis Alliance exists to reduce the global burden of sepsis through advocacy, education, innovation, and international collaboration. Our activities deliver clear public benefit by raising awareness of sepsis among healthcare professionals, policymakers, and the general public; promoting early recognition and timely treatment; supporting survivors and families; and contributing to the development of global health policy. Through free access to high-quality educational resources such as the World Sepsis Congress, collaboration with the World Health Organization and national governments, and support for regional alliances, we help improve sepsis outcomes worldwide - particularly in low- and middle-income countries, where the burden is greatest.

Our work aligns with public health priorities, advances the Sustainable Development Goals, and ultimately saves lives by informing and empowering both professionals and communities to act on sepsis.

Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2025

Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What Examples Exist of Who Has Benefited?

A wide range of individuals and communities have benefited from the work of the Global Sepsis Alliance. Healthcare professionals worldwide - particularly in low- and middle-income countries - have gained free access to the latest clinical knowledge and research through our educational events, such as the World Sepsis Congress and thematic symposia. Policymakers and public health authorities have drawn on our guidance and advocacy to develop or enhance national sepsis strategies, as seen with the SEPSIS Act in the United States and the launch of the 2030 Global Agenda for Sepsis. Sepsis survivors and their families have also benefited through platforms that amplify their voices, connect them with support networks, and raise public awareness. Additionally, organizations such as the Caribbean Sepsis and AMR Alliance have emerged with GSA support, enabling local responses to regional sepsis challenges. Collectively, these examples demonstrate how our work directly supports professionals, policymakers, and the public in reducing the harm caused by sepsis.

PLANS FOR FUTURE PERIODS

In 2026, the Global Sepsis Alliance (GSA) will continue to strengthen its position as a global leader in sepsis advocacy, education, and partnership building, with a particular focus on translating increased international awareness into sustained policy action and measurable health system improvements.

A key priority will be to further elevate sepsis on regional and global political agendas. GSA will continue its engagement with the World Health Organization, United Nations agencies, governments, and international partners to promote the integration of sepsis into broader health system strengthening, pandemic preparedness, and antimicrobial resistance strategies.

The European Sepsis Alliance will intensify its advocacy efforts at the European level, including engagement with the Irish Presidency of the Council of the European Union, with the aim of advancing coordinated action on sepsis across Europe.

GSA will continue to expand its educational activities through webinars, expert discussions, and freely accessible digital resources, ensuring that healthcare professionals, researchers, policymakers, and patient advocates worldwide have access to current evidence and best practices in sepsis prevention, diagnosis, and treatment.

A major priority for 2026 will be the organization and execution of the 6th World Sepsis Congress, to be held in April 2026 under the theme "Universal Sepsis Care for Newborns, Children, and Women". As GSA's flagship educational initiative, the free, fully virtual congress will bring together healthcare professionals, researchers, policymakers, patient advocates, survivors, and representatives from international organizations from around the world.

The congress will focus on improving equitable access to high-quality sepsis prevention, diagnosis, and treatment for some of the most vulnerable populations, while promoting multidisciplinary collaboration and the exchange of best practices. By ensuring unrestricted global access, GSA aims to strengthen knowledge sharing, support capacity building, and advance progress towards universal sepsis care worldwide.

The organization will further develop the Global Sepsis Innovations Platform (GSIP) to accelerate collaboration between researchers, clinicians, industry partners, innovators, and people with lived experience. Particular emphasis will be placed on supporting innovations in diagnostics, artificial intelligence, implementation science, and health system delivery.

Building on the successful establishment of the Global Sepsis Survivor Committee, GSA will strengthen survivor engagement and ensure that the perspectives of survivors and family members remain central to its advocacy and program development.

The Individual Membership Program, launched in 2025, will continue to be expanded to foster a broader global community of supporters and increase opportunities for participation in GSA activities.

World Sepsis Day will remain a flagship awareness initiative in 2026, with GSA supporting global campaigns and coordinating international events to increase public awareness and encourage policy action at national and international levels.

The organization will also continue to strengthen its network of member organizations, Regional Sepsis Alliances, and strategic partners, with the aim of fostering greater collaboration and accelerating progress towards reducing preventable sepsis deaths and disabilities worldwide.

Through these activities, GSA aims to further advance its vision of a world free of sepsis and contribute to achieving sustainable, equitable improvements in sepsis prevention, recognition, and care globally.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr Philip Taylor

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2025

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

RAA Avalon Accounting Ltd
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Executive Committee

Abdulelah Alhawsawi
Dennis Kredler
Imrana Malik
Maha Aljuaid
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Ally Hossain, Andrew Argent, Antonio Artigas, Ciaran Staunton, Dennis Kredler, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Rafael Barberena Moraes, Ron Daniels, Sheila Myatra, Shevin Jacob, Steve McGloughlin, Tex Kissoon, Ulrika Knutsson.

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Caroline Brazier

RAA Avalon Accounting Ltd
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2025

		2025 Unrestricted fund £	2024 Total funds £
	Notes		
Income and endowments from			
Donations and legacies	2	308,583	67,357
Other trading activities	3	56,617	51,865
Total		<u>365,200</u>	<u>119,222</u>
 Expenditure on			
Raising funds	4	325,586	448,677
 NET INCOME/(EXPENDITURE)		 39,614	 (329,455)
 Reconciliation of funds			
Total funds brought forward		146,548	476,003
 Total funds carried forward		 <u>186,162</u>	 <u>146,548</u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2025

		2025	2024
		Unrestricted	Total
		fund	funds
	Notes	£	£
Fixed assets			
Tangible assets	9	7,373	9,831
Current assets			
Debtors	10	157,458	127,569
Cash at bank		25,009	27,088
		182,467	154,657
Creditors			
Amounts falling due within one year	11	(3,678)	(17,940)
Net current assets		178,789	136,717
Total assets less current liabilities		186,162	146,548
NET ASSETS		186,162	146,548
Funds	12		
Unrestricted funds		186,162	146,548
Total funds		186,162	146,548

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet - continued
31 December 2025

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Notes to the Financial Statements
for the Year Ended 31 December 2025

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

2. DONATIONS AND LEGACIES

	2025	2024
	£	£
Donations	308,583	67,357
	<u> </u>	<u> </u>

3. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Sponsorships	56,617	51,865
	<u> </u>	<u> </u>

4. RAISING FUNDS

RAISING DONATIONS AND LEGACIES

	2025	2024
	£	£
Postage and stationery	1,423	3,498
Other direct cost	8,811	1,553
Travel subsistence & accommodation	18,363	11,339
Event costs	57,692	62,279
Support costs	239,297	370,008
	<u> </u>	<u> </u>
	325,586	448,677
	<u> </u>	<u> </u>

5. SUPPORT COSTS

	Management	Finance	Information technology
	£	£	£
Raising donations and legacies	221,121	825	5,833
	<u> </u>	<u> </u>	<u> </u>
	Other	Other 2	Governance costs
	£	£	£
Raising donations and legacies	2,458	3,725	5,335
	<u> </u>	<u> </u>	<u> </u>
			Totals
			£
			239,297
			<u> </u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2025	2024
	£	£
Depreciation - owned assets	2,458	3,277
	<u> </u>	<u> </u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2025 nor for the year ended 31 December 2024.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2025 nor for the year ended 31 December 2024.

8. STAFF COSTS

	2025	2024
	£	£
Wages and salaries	150,906	238,053
	<u>150,906</u>	<u>238,053</u>

The average monthly number of employees during the year was as follows:

2025	2024
<u> </u>	<u> </u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery	Fixtures and fittings	Computer equipment	Totals
	£	£	£	£
COST				
At 1 January 2025 and 31 December 2025	1,710	8,172	25,238	35,120
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
DEPRECIATION				
At 1 January 2025	879	6,872	17,538	25,289
Charge for year	208	325	1,925	2,458
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
At 31 December 2025	1,087	7,197	19,463	27,747
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
NET BOOK VALUE				
At 31 December 2025	623	975	5,775	7,373
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
At 31 December 2024	831	1,300	7,700	9,831
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Trade debtors	137,894	108,037
Investment	18,639	18,639
VAT	925	893
	<u>157,458</u>	<u>127,569</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Social security and other taxes	1,574	3,832
Other creditors	94	-
Net wages	-	12,248
Accrued expenses	2,010	1,860
	<u>3,678</u>	<u>17,940</u>

12. MOVEMENT IN FUNDS

	At 1.1.25	Net movement in funds	At 31.12.25
	£	£	£
Unrestricted funds			
General fund	146,548	39,614	186,162
	<u>146,548</u>	<u>39,614</u>	<u>186,162</u>
TOTAL FUNDS	<u>146,548</u>	<u>39,614</u>	<u>186,162</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	365,200	(325,586)	39,614
	<u>365,200</u>	<u>(325,586)</u>	<u>39,614</u>
TOTAL FUNDS	<u>365,200</u>	<u>(325,586)</u>	<u>39,614</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.24 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	476,003	(329,455)	146,548
TOTAL FUNDS	476,003	(329,455)	146,548

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	119,222	(448,677)	(329,455)
TOTAL FUNDS	119,222	(448,677)	(329,455)

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.24 £	Net movement in funds £	At 31.12.25 £
Unrestricted funds			
General fund	476,003	(289,841)	186,162
TOTAL FUNDS	476,003	(289,841)	186,162

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	484,422	(774,263)	(289,841)
TOTAL FUNDS	484,422	(774,263)	(289,841)

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,325 (PY - £3,600). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2025

	2025 £	2024 £
Income and endowments		
Donations and legacies		
Donations	308,583	67,357
Other trading activities		
Sponsorships	56,617	51,865
Total incoming resources	365,200	119,222
Expenditure		
Raising donations and legacies		
Postage and stationery	1,423	3,498
Other direct cost	8,811	1,553
Travel subsistence & accommodation	18,363	11,339
Event costs	57,692	62,279
	86,289	78,669
Support costs		
Management		
Wages	150,906	238,053
Computer Cost	3,670	6,155
Insurance	34,757	49,719
Office Rent	17,144	15,789
Staff welfare	-	240
Telephone	861	813
Advertising	1,656	-
Office cost	-	719
Bookkeeping	1,224	1,035
Consultancy	7,393	35,501
Foreign Exchange Loss	3,510	4,892
	221,121	352,916
Finance		
Light and heat	275	120
Sundry Expense	34	-
Bank charges	364	286
Paypal charges	152	102
	825	508

This page does not form part of the statutory financial statements

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2025

	2025 £	2024 £
Finance		
Information technology		
Website development	5,833	5,866
Other		
Plant and machinery	208	277
Fixtures and fittings	325	433
Computer equipment	1,925	2,567
	2,458	3,277
Other 2		
Subscription	3,725	1,981
Governance costs		
Accountancy fees	2,010	1,860
Secretary	3,325	3,600
	5,335	5,460
Total resources expended	325,586	448,677
Net income/(expenditure)	<u>39,614</u>	<u>(329,455)</u>

This page does not form part of the statutory financial statements

Accounts

REGISTERED COMPANY NUMBER: 07476120 (England and Wales)
REGISTERED CHARITY NUMBER: 1142803

Trustees' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2024
for
Global Sepsis Alliance

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2024

	Page
Trustees' Report	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9 to 10
Notes to the Financial Statements	11 to 16
Detailed Statement of Financial Activities	17 to 18

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research, and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate

range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring Our Work Delivers Our Aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees, Board, and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

Annual Activity Report - 2024 Highlights

Throughout 2024, the Global Sepsis Alliance undertook a wide range of initiatives to advance its mission of reducing the global burden of sepsis. The following summary outlines our most significant activities and achievements over the year:

Policy and Advocacy

WHO and UN Engagement: GSA's CEO, Dr. Mariam Jashi, addressed both the 154th Session of the WHO Executive Board and the 77th World Health Assembly to advocate for the inclusion of sepsis in Universal Health Coverage frameworks. GSA also participated in the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance and hosted a side event during UNGA79.

Launch of the 2030 Global Agenda for Sepsis: This initiative was formally launched in September at the German Parliament, outlining a comprehensive strategic framework to reduce sepsis deaths and long-term consequences by 2030.

Legislative Momentum in the United States: The SEPSIS Act, a bipartisan bill to enhance sepsis programs and systems, was introduced to the U.S. Senate in September with cross-party sponsorship. In parallel, the U.S. Congress allocated \$3 million to the CDC for national sepsis advocacy.

EU and Global Outreach: GSA led sepsis discussions at the UNITE Parliamentarians Global Summit, participated in the World Health Summit, and contributed to a joint sepsis policy call published in The Lancet, urging EU leaders to adopt a European Sepsis Plan.

Scientific and Clinical Leadership

2024 World Sepsis Congress Spotlight: Held in April, this online event focused on the unmet need in sepsis diagnosis and therapy. It featured nine thematic sessions covering personalized medicine, biomarkers, pediatric sepsis, AI-based prediction models, and the newly published 'Phoenix Criteria' for pediatric diagnosis. The event attracted over 12,000 participants from 185 countries, with 65% from low- and middle-income countries.

Symposium on Sepsis and the Immune System: Organized jointly with Sepsis Stiftung, this scientific symposium examined the dual role of the immune system in sepsis pathophysiology and therapeutic approaches.

Strategic Engagement with WHO: GSA contributed to the launch of WHO's website on clinical sepsis management and joined the WHO Acute Care Action Network (ACAN) to strengthen advocacy and capacity-building in acute care settings.

Partnerships and Strategic Alliances

Caribbean Sepsis Alliance Launch: GSA supported the formal establishment of the Caribbean Sepsis Alliance, with its inaugural event focusing on the intersections of climate change, health equity, and sepsis.

Memorandum of Understanding with MWIA: On International Women's Day, GSA signed a strategic partnership agreement with the Medical Women's International Association to promote gender equity and women's leadership in global health and sepsis policy.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2024

Collaborations with UNICEF and UNDP: High-level meetings with global health leaders, including UNICEF's Director of Health and representatives from the United Nations Development Programme, were held to explore joint approaches to sepsis prevention and maternal-child health.

Awareness and Public Engagement

World Sepsis Day 2024: Hundreds of awareness events were organized globally. Highlights included a video address from the WHO Director-General and formal recognition of sepsis by national health leaders. GSA also launched a virtual photo booth and published a global event poster showcasing participating organizations.

Sepsis Survivor Advocacy: GSA coordinated meetings between sepsis survivors and WHO leadership and supported survivor-led advocacy initiatives, underscoring the human impact of sepsis and the need for systemic change.

Media and Publications: GSA published full reports on its major events and initiatives and continued to provide open-access educational resources via video and podcast platforms.

Innovation and Capacity Building

Launch of the Global Sepsis Innovations Platform (GSIP): In December, GSA opened expressions of interest for its new platform focused on catalyzing innovations in sepsis diagnostics, therapies, and digital health solutions.

Inauguration of the GSA Fellowship Program: Aimed at fostering the next generation of sepsis leaders, the program was formally announced in October and is set to commence in 2025.

Governance and Stakeholder Engagement

Throughout the year, GSA held regular consultations with its members, Board of Directors, sponsors, and strategic partners. These engagements informed priority-setting for the year ahead and further strengthened GSA's collaborative approach to global advocacy.

How Our Activities Deliver Public Benefit

The Global Sepsis Alliance exists to reduce the global burden of sepsis through advocacy, education, innovation, and international collaboration. Our activities deliver clear public benefit by raising awareness of sepsis among healthcare professionals, policymakers, and the general public; promoting early recognition and timely treatment; supporting survivors and families; and contributing to the development of global health policy. Through free access to high-quality educational resources such as the World Sepsis Congress, collaboration with the World Health Organization and national governments, and support for regional alliances, we help improve sepsis outcomes worldwide - particularly in low- and middle-income countries, where the burden is greatest.

Our work aligns with public health priorities, advances the Sustainable Development Goals, and ultimately saves lives by informing and empowering both professionals and communities to act on sepsis.

Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly.

Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What Examples Exist of Who Has Benefited?

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2024

A wide range of individuals and communities have benefited from the work of the Global Sepsis Alliance. Healthcare professionals worldwide - particularly in low- and middle-income countries - have gained free access to the latest clinical knowledge and research through our educational events, such as the World Sepsis Congress and thematic symposia. Policymakers and public health authorities have drawn on our guidance and advocacy to develop or enhance national sepsis strategies, as seen with the SEPSIS Act in the United States and the launch of the 2030 Global Agenda for Sepsis. Sepsis survivors and their families have also benefited through platforms that amplify their voices, connect them with support networks, and raise public awareness. Additionally, organizations such as the Caribbean Sepsis and AMR Alliance have emerged with GSA support, enabling local responses to regional sepsis challenges. Collectively, these examples demonstrate how our work directly supports professionals, policymakers, and the public in reducing the harm caused by sepsis.

PLANS FOR FUTURE PERIODS

In 2025, the Global Sepsis Alliance will continue to expand its impact through key initiatives aimed at innovation, collaboration, and policy advancement. A central focus will be the 5th World Sepsis Congress in April, featuring over 90 expert speakers addressing cutting-edge research, personalized medicine, and global strategies for infection prevention. We will formally launch the Global Sepsis Innovations Platform (GSIP) to drive advancements in diagnostics, therapies, and digital health. In parallel, we will strengthen partnerships with international institutions, support regional alliances, and advocate for the integration of sepsis into national health plans, particularly in underserved regions. These efforts aim to accelerate progress toward the 2030 Global Agenda for Sepsis.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr Philip Taylor

Independent Examiner

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2024

REFERENCE AND ADMINISTRATIVE DETAILS

Executive Committee

Abdulelah Alhawsawi
Brett Abbenbroek
Daniela Souza
Dennis Kredler
Emmanuel Nsutebu - (Deceased November 2024)
Imrana Malik
Maha Aljuaid
Niranjan 'Tex' Kissoon
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Antonio Artigas, Brett Abbenbroek, Daniela Souza, Dennis Kredler, Emmanuel Nsutebu - (Deceased November 2024), Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Louise Thwaites, Luis Antonio Gorordo Del Sol, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Niranjan 'Tex' Kissoon, Ron Daniels, Shevin Jacob, Tobias Welte - (Deceased March 2024), Ulrika Knutsson

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Sanjay Swarup

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2024

		2024	2023
		Unrestricted	Total
	Notes	fund	funds
		£	£
Income and endowments from			
Donations and legacies	2	67,357	273,926
Other trading activities	3	51,865	48,431
Total		<u>119,222</u>	<u>322,357</u>
 Expenditure on			
Raising funds	4	448,677	476,889
 NET INCOME/(EXPENDITURE)		 (329,455)	 (154,532)
 Reconciliation of funds			
Total funds brought forward		476,003	630,535
 Total funds carried forward		 <u>146,548</u>	 <u>476,003</u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2024

		2024	2023
		Unrestricted	Total
		fund	funds
	Notes	£	£
Fixed assets			
Tangible assets	9	9,831	10,101
Current assets			
Debtors	10	127,569	124,329
Cash at bank		27,088	346,918
		154,657	471,247
Creditors			
Amounts falling due within one year	11	(17,940)	(5,345)
Net current assets		136,717	465,902
Total assets less current liabilities		146,548	476,003
NET ASSETS		146,548	476,003
Funds	12		
Unrestricted funds		146,548	476,003
Total funds		146,548	476,003

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet - continued

31 December 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. DONATIONS AND LEGACIES

	2024	2023
	£	£
Donations	67,357	273,926

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

3. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Sponsorships	<u>51,865</u>	<u>48,431</u>

4. RAISING FUNDS

RAISING DONATIONS AND LEGACIES

	2024	2023
	£	£
Postage and stationery	3,498	2,810
Other direct cost	1,553	79,760
Travel subsistence & accommodation	11,339	19,053
Event costs	62,279	101,169
Support costs	<u>370,008</u>	<u>274,097</u>
	<u>448,677</u>	<u>476,889</u>

5. SUPPORT COSTS

	Management	Finance	Information
	£	£	technology
Raising donations and legacies	<u>352,916</u>	<u>508</u>	<u>5,866</u>
	Other	Other 2	Governance
	£	£	costs
Raising donations and legacies	<u>3,277</u>	<u>1,981</u>	<u>5,460</u>
			Totals
			£
			<u>370,008</u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Depreciation - owned assets	<u>3,277</u>	<u>3,367</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2024 nor for the year ended 31 December 2023.

8. STAFF COSTS

	2024	2023
	£	£
Wages and salaries	238,053	146,054
	<u>238,053</u>	<u>146,054</u>

The average monthly number of employees during the year was as follows:

2024	2023
<u> </u>	<u> </u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery	Fixtures and fittings	Computer equipment	Totals
	£	£	£	£
COST				
At 1 January 2024	838	8,172	23,103	32,113
Additions	872	-	2,135	3,007
	<u>1,710</u>	<u>8,172</u>	<u>25,238</u>	<u>35,120</u>
At 31 December 2024	1,710	8,172	25,238	35,120
DEPRECIATION				
At 1 January 2024	602	6,439	14,971	22,012
Charge for year	277	433	2,567	3,277
	<u>879</u>	<u>6,872</u>	<u>17,538</u>	<u>25,289</u>
At 31 December 2024	879	6,872	17,538	25,289
NET BOOK VALUE				
At 31 December 2024	<u>831</u>	<u>1,300</u>	<u>7,700</u>	<u>9,831</u>
At 31 December 2023	<u>236</u>	<u>1,733</u>	<u>8,132</u>	<u>10,101</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade debtors	108,037	104,590
Investment	18,639	18,639
VAT	893	1,100
	<u>127,569</u>	<u>124,329</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Social security and other taxes	3,832	3,575
Net wages	12,248	-
Accrued expenses	1,860	1,770
	<u>17,940</u>	<u>5,345</u>

12. MOVEMENT IN FUNDS

	At 1.1.24	Net movement in funds	At 31.12.24
	£	£	£
Unrestricted funds			
General fund	476,003	(329,455)	146,548
	<u>476,003</u>	<u>(329,455)</u>	<u>146,548</u>
TOTAL FUNDS	<u>476,003</u>	<u>(329,455)</u>	<u>146,548</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	119,222	(448,677)	(329,455)
	<u>119,222</u>	<u>(448,677)</u>	<u>(329,455)</u>
TOTAL FUNDS	<u>119,222</u>	<u>(448,677)</u>	<u>(329,455)</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	630,535	(154,532)	476,003
TOTAL FUNDS	<u>630,535</u>	<u>(154,532)</u>	<u>476,003</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	322,357	(476,889)	(154,532)
TOTAL FUNDS	<u>322,357</u>	<u>(476,889)</u>	<u>(154,532)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.23 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	630,535	(483,987)	146,548
TOTAL FUNDS	<u>630,535</u>	<u>(483,987)</u>	<u>146,548</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	441,579	(925,566)	(483,987)
TOTAL FUNDS	<u>441,579</u>	<u>(925,566)</u>	<u>(483,987)</u>

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,600 (PY - £3,450). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2024

	2024 £	2023 £
Income and endowments		
Donations and legacies		
Donations	67,357	273,926
Other trading activities		
Sponsorships	51,865	48,431
Total incoming resources	119,222	322,357
Expenditure		
Raising donations and legacies		
Postage and stationery	3,498	2,810
Other direct cost	1,553	79,760
Travel subsistence & accommodation	11,339	19,053
Event costs	62,279	101,169
	78,669	202,792
Support costs		
Management		
Wages	238,053	146,054
Computer Cost	6,155	14,855
Insurance	49,719	30,546
Office Rent	15,789	14,818
Staff welfare	240	274
Telephone	813	2,894
Advertising	-	5,794
Office cost	719	-
Bookkeeping	1,035	924
Consultancy	35,501	34,645
Foreign Exchange Loss	4,892	2,821
	352,916	253,625
Finance		
Light and heat	120	-
Bank charges	286	288
Paypal charges	102	309
	508	597
Information technology		
Website development	5,866	5,504

This page does not form part of the statutory financial statements

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2024

	2024 £	2023 £
Information technology		
Other		
Plant and machinery	277	78
Fixtures and fittings	433	578
Computer equipment	2,567	2,711
	3,277	3,367
 Other 2		
Subscription	1,981	1,320
 Governance costs		
Membership fees	-	4,464
Accountancy fees	1,860	1,770
Secretary	3,600	3,450
	5,460	9,684
 Total resources expended	448,677	476,889
 Net expenditure	 (329,455)	 (154,532)

This page does not form part of the statutory financial statements

Accounts

REGISTERED COMPANY NUMBER: 07476120 (England and Wales)
REGISTERED CHARITY NUMBER: 1142803

Trustees' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2023
for
Global Sepsis Alliance

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2023

	Page
Trustees' Report	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9 to 10
Notes to the Financial Statements	11 to 16
Detailed Statement of Financial Activities	17 to 18

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research, and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate a range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring Our Work Delivers Our Aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

The Focus of Our Work

Our main objectives for the year 2023 continued to be those activities aimed at raising awareness and understanding of sepsis and its treatment, as well as igniting necessary policy changes and mental shifts in policymakers and governmental institutions, especially those involved in policymaking. These objectives are how we will actively pursue our vision:

A WORLD FREE OF SEPSIS

The strategies we used to meet these objectives included:

- working closely with the WHO and national governments towards having the World Health Assembly (WHA) adopt a resolution on sepsis. This was achieved in May 2017 at the 70th WHA, marking a quantum leap in the global fight against sepsis which was spearheaded by the GSA
- working closely with the WHO and national governments to implement the demands of said WHA Resolution on Sepsis; especially fostering national sepsis strategies, and the integration of sepsis in existing health strategies
- the instigation of the first World Sepsis Day in September 2012 which is now a recurring annual event involving more than 80 countries and more than 400 events
- working to get World Sepsis Day officially recognized as a World Health Day by the World Health Organization
- the instigation of the Global Sepsis Awards in 2015, which is now a recurring initiative to highlight sepsis related projects and achievements on a global level each year
- the establishment of World Sepsis Congress in 2016 and World Sepsis Congress Spotlight in 2017. These free online conferences make knowledge about sepsis accessible to all parts of the world
- In 2023, we hosted the 4th World Sepsis Congress, titled "One Global Health Threat: Sepsis, Pandemics, and Antimicrobial Resistance" in April of 2023. The 4th WSC attracted more than 15,400 registrations from 187 countries, and featured 16 sessions and 99 speakers, moderators, and panelists. All talks are available for free on YouTube and as a podcast.
- the development and continuous maintenance and updating of websites for World Sepsis Day (www.worldsepsisday.org), World Sepsis Congress (www.worldsepsiscongress.org), WSC Spotlight (www.wscspotlight.org) as well as the Global Sepsis Alliance (<http://www.globalsepsisalliance.org>)
- the development and publication of the World Sepsis Declaration, which was recently updated with goals and targets for 2030 and serves as our North Star
- the development and publication of relevant and timely news posts on our WSD and GSA websites, an email newsletter, as well as the use of social media, especially X (formerly Twitter), Instagram, LinkedIn, TikTok, and Facebook
- sharing stories of people impacted by sepsis on our website and on social media;
- growing the network of the GSA (over 120 members at the end of 2023)
- working towards applying international standards and guidelines, in close connection to the demands of the before-mentioned resolution

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2023

-working in partnership with other organizations and agencies to secure the widest range of initiatives and encouraging action on sepsis.

Briefly mentioned above, of huge significance in 2023 was the 4th World Sepsis Congress - over the course of two days and 16 diverse and highly relevant sessions, 99 speakers, panelists, and moderators from more than 35 countries presented on all aspects of sepsis, including the link to pandemics and AMR, the role of AI (artificial intelligence), ML (machine learning), big data, patient safety, the impact of policy, novel trial design, the latest research, and much more. The congress took place entirely online and participation was free of charge, allowing participants to join from wherever they had an internet connection. The congress was an astonishing success, with more than 15,400 registrations from 187 countries. More than 60% of our audience joined from low- and middle-income countries (LMIC) - the majority of whom could not have afforded to travel to a physical congress to learn about sepsis. All presentations were recorded and continue to be available on our YouTube channel and on Apple Podcasts, easily accessible and free of charge. For the first time ever, the 4th WSC was CME-accredited. We plan to host the 2024 WSC Spotlight in April 2024 and the 5th World Sepsis Congress in April 2025.

Throughout the year, the GSA also supported and promoted other health days with a relationship to sepsis, such as World Hand Hygiene Day, World Patient Safety Day, and virtually all other World Health Days and their respective campaigns. In March, we translated our 'What Is Sepsis?'-Video into Korean (it's also available in English, Spanish, Portuguese, French, Italian, Turkish, German, Arabic, and Russian). Towards the end of March, we supported our friends and colleagues from the European Sepsis Alliance hosting their 6th Annual Meeting live from Brussels.

The GSA also kept on supporting and growing its regional sepsis alliances - including their events, such as webinars and physical meetings. Gearing up for World Sepsis Day, we again launched an interactive virtual photo booth - a super fun and engaging way to participate in WSD online.

In addition to facilitating hundreds of events celebrating sepsis awareness and World Sepsis Day all over the world, by inspiring our worldwide network of supporters, providing ideas and material, we also hosted an event in Germany. Said event was titled "The Enactment of the WHO Sepsis on the National and International Level" and held in Berlin in collaboration with the 'Germany Recognizes Sepsis'-coalition, the European Sepsis Alliance, and the Sepsis Stiftung.

Leading up to the event, we were able to receive welcome remarks from Dr. Tedros, WHO Director-General and release the Berlin Declaration. The Berlin Declaration calls for the urgent enforcement of the WHA Resolution on Sepsis and reinvigorated global action on sepsis and has been signed by over 75 organizations from all over the world.

Towards the end of September, we flew to New York for the 78th United Nations General Assembly - precisely, to host the first-ever High-Level Side Event on Sepsis, titled 'Synergizing Global Actions for Sepsis, AMR, and PPPR for Attaining Health Related SDGs'. Serving as a platform for fostering collaboration and innovation in the fight against sepsis and antimicrobial resistance (AMR), and promoting public-private partnerships for health-related SDGs, this pivotal gathering was co-hosted by the Clinton Health Access Initiative, the Global Antibiotic Research & Development Partnership, the Global Sepsis Alliance, the Medical Women's International Association, the Sepsis Stiftung, UNITE, and the Virchow Foundation for Global Health.

In October, we convened a High-Level Luncheon on Sepsis on the Margins of the 2023 World Health Summit, bringing together senior officials from Parliaments, Governments, UN agencies, The G20 & G7 Health and Development Partnership, civil society, the private sector, and academia.

In November - and in collaboration with the Charité - Universitätsmedizin Berlin - we hosted another event, the free live stream of 'Lessons From the COVID-19 Pandemic', featuring Dr. Uzma Syed, and Prof. Konrad Reinhart, as well as a panel discussion on 'Key Lessons on Pandemic Preparedness and Response to Non-Covid Sepsis' with inspiring thought leaders in global health, focusing on the interrelated topics of pandemics, covid, and sepsis.

Over the year, we also released new material on sepsis, such as updated infographics, as well as translated our existing sepsis awareness material to more languages.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2023

How Our Activities Deliver Public Benefit

Our main activities and who we try to help are described above. All our charitable activities focus on raising awareness and understanding of sepsis and its treatment and this remains our key challenge. All our activities are undertaken to further our charitable purposes for the public benefit. Despite advances in modern medicine, including vaccines, antibiotics, and intensive care, sepsis remains the primary cause of death from infection, including viral infections such as COVID-19. Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly. Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What Examples Exist of Who Has Benefited?

In 2012, the Ropy Staunton Foundation and Global Sepsis Alliance announced that they will unite to fight against sepsis, claims 17 deaths per minute, 24,480 deaths every day and 8-9 million lives annually. Our collaboration has continued into 2021 to create global sepsis awareness and mandates. 12-year-old Ropy scratched his elbow playing school basketball on March 29th, 2012. He soon became unwell and, having previously been sent home from a leading New York hospital, died four days later from unrecognized sepsis.

We formed a Communications Committee under the leadership of Dr Ron Daniels. This Committee was formed to recognize that public awareness is created through action and communication. The Committee will help to further develop ideas and our communications strategy to the press and social media over the whole year and especially around World Sepsis Day. Our efforts on social media are going well, with double-digit growth on Twitter, Facebook, and Instagram. The GSA also has a Quality Improvement Committee (QIC), focusing on research and quality improvement. That includes better protocols in hospitals to detect sepsis earlier, when it is easier to treat and manage.

PLANS FOR FUTURE PERIODS

The charity plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements. We plan to host another the 2024 World Sepsis Congress Spotlight in April 2024, as well as the 5th World Sepsis Congress in April 2025. All other projects, for example WSD and the GSA Awards, will be continued in 2023.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr. Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr. Philip Taylor

Independent Examiner

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2023

REFERENCE AND ADMINISTRATIVE DETAILS

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Executive Committee

Abdulelah Alhawsawi
Brett Abbenbroek
Daniela Souza
Dennis Kredler
Emmanuel Nsutebu
Imrana Malik
Maha Aljuaid
Niranjan 'Tex' Kissoon
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Antonio Artigas, Brett Abbenbroek, Daniela Souza, Dennis Kredler, Emmanuel Nsutebu, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Louise Thwaites, Luis Antonio Gorordo Del Sol, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Niranjan 'Tex' Kissoon, Ron Daniels, Shevin Jacob, Tobias Welte, Ulrika Knutsson

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr. Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Sanjay Swarup

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2023

		2023 Unrestricted fund £	2022 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies	2	273,926	198,833
Other trading activities	3	48,431	55,277
Total		<u>322,357</u>	<u>254,110</u>
 EXPENDITURE ON			
Raising funds	4	476,889	373,060
		<u> </u>	<u> </u>
NET INCOME/(EXPENDITURE)		(154,532)	(118,950)
 RECONCILIATION OF FUNDS			
Total funds brought forward		630,535	749,485
		<u> </u>	<u> </u>
TOTAL FUNDS CARRIED FORWARD		<u><u>476,003</u></u>	<u><u>630,535</u></u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2023

	Notes	2023 Unrestricted fund £	2022 Total funds £
FIXED ASSETS			
Tangible assets	9	10,101	10,162
CURRENT ASSETS			
Debtors	10	124,329	79,706
Cash at bank		346,918	548,561
		471,247	628,267
CREDITORS			
Amounts falling due within one year	11	(5,345)	(7,894)
NET CURRENT ASSETS		465,902	620,373
TOTAL ASSETS LESS CURRENT LIABILITIES		476,003	630,535
NET ASSETS		476,003	630,535
FUNDS	12		
Unrestricted funds		476,003	630,535
TOTAL FUNDS		476,003	630,535

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet - continued

31 December 2023

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Mr. Philip Taylor - Trustee

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. DONATIONS AND LEGACIES

	2023	2022
	£	£
Donations	273,926	198,833

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

3. OTHER TRADING ACTIVITIES

	2023	2022
	£	£
Sponsorships	48,431	55,277

4. RAISING FUNDS

RAISING DONATIONS AND LEGACIES

	2023	2022
	£	£
Postage and stationery	2,810	1,841
Other direct cost	79,760	3,646
Travel subsistence & accommodation	19,053	3,179
Event costs	101,169	96,594
Support costs	274,097	267,800
	<u>476,889</u>	<u>373,060</u>

5. SUPPORT COSTS

	Management	Finance	Information technology
	£	£	£
Raising donations and legacies	253,625	597	5,504
	<u>253,625</u>	<u>597</u>	<u>5,504</u>
		Governance	
	Other	Other 2	Totals
	£	£	£
Raising donations and legacies	3,367	1,320	9,684
	<u>3,367</u>	<u>1,320</u>	<u>9,684</u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2023	2022
	£	£
Depreciation - owned assets	3,367	3,388

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022.

8. STAFF COSTS

	2023	2022
	£	£
Wages and salaries	146,054	168,656
	<u>146,054</u>	<u>168,656</u>

The average monthly number of employees during the year was as follows:

	2023	2022
	-	8
Employees	<u>-</u>	<u>8</u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery £	Fixtures and fittings £	Computer equipment £	Totals £
COST				
At 1 January 2023	838	8,172	19,797	28,807
Additions	-	-	3,306	3,306
	<u>838</u>	<u>8,172</u>	<u>23,103</u>	<u>32,113</u>
At 31 December 2023	838	8,172	23,103	32,113
DEPRECIATION				
At 1 January 2023	524	5,861	12,260	18,645
Charge for year	78	578	2,711	3,367
	<u>602</u>	<u>6,439</u>	<u>14,971</u>	<u>22,012</u>
At 31 December 2023	602	6,439	14,971	22,012
NET BOOK VALUE				
At 31 December 2023	<u>236</u>	<u>1,733</u>	<u>8,132</u>	<u>10,101</u>
At 31 December 2022	<u>314</u>	<u>2,311</u>	<u>7,537</u>	<u>10,162</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Trade debtors	104,590	60,398
Investment	18,639	18,639
VAT	1,100	669
	<u>124,329</u>	<u>79,706</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Social security and other taxes	3,575	6,209
Accrued expenses	1,770	1,685
	<u>5,345</u>	<u>7,894</u>

12. MOVEMENT IN FUNDS

	At 1.1.23	Net movement in funds	At 31.12.23
	£	£	£
Unrestricted funds			
General fund	630,535	(154,532)	476,003
	<u>630,535</u>	<u>(154,532)</u>	<u>476,003</u>
TOTAL FUNDS	<u>630,535</u>	<u>(154,532)</u>	<u>476,003</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	322,357	(476,889)	(154,532)
	<u>322,357</u>	<u>(476,889)</u>	<u>(154,532)</u>
TOTAL FUNDS	<u>322,357</u>	<u>(476,889)</u>	<u>(154,532)</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.22	Net movement in funds	At 31.12.22
	£	£	£
Unrestricted funds			
General fund	749,485	(118,950)	630,535
TOTAL FUNDS	<u>749,485</u>	<u>(118,950)</u>	<u>630,535</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	254,110	(373,060)	(118,950)
TOTAL FUNDS	<u>254,110</u>	<u>(373,060)</u>	<u>(118,950)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.22	Net movement in funds	At 31.12.23
	£	£	£
Unrestricted funds			
General fund	749,485	(273,482)	476,003
TOTAL FUNDS	<u>749,485</u>	<u>(273,482)</u>	<u>476,003</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	576,467	(849,949)	(273,482)
TOTAL FUNDS	<u>576,467</u>	<u>(849,949)</u>	<u>(273,482)</u>

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,450 (PY - £3,000). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2023

	2023 £	2022 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	273,926	198,833
Other trading activities		
Sponsorships	48,431	55,277
Total incoming resources	322,357	254,110
EXPENDITURE		
Raising donations and legacies		
Postage and stationery	2,810	1,841
Other direct cost	79,760	3,646
Travel subsistence & accommodation	19,053	3,179
Event costs	101,169	96,594
	202,792	105,260
Support costs		
Management		
Wages	146,054	168,656
Computer Cost	14,855	5,785
Insurance	30,546	39,276
Office Rent	14,818	9,987
Staff welfare	274	79
Telephone	2,894	859
Advertising	5,794	5,146
Office cost	-	266
Bookkeeping	924	768
Consultancy	34,645	2,000
Foreign Exchange Loss	2,821	(1,327)
	253,625	231,495
Finance		
Bank charges	288	336
Paypal charges	309	112
	597	448
Information technology		
Website development	5,504	5,806

This page does not form part of the statutory financial statements

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2023

	2023 £	2022 £
Information technology		
Other		
Plant and machinery	78	105
Fixtures and fittings	578	770
Computer equipment	2,711	2,513
	3,367	3,388
 Other 2		
Subscription	1,320	2,223
 Governance costs		
Membership fees	4,464	19,755
Accountancy fees	1,770	1,685
Secretary	3,450	3,000
	9,684	24,440
 Total resources expended	476,889	373,060
 Net expenditure	 (154,532)	 (118,950)

This page does not form part of the statutory financial statements

Accounts

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31 December 2022
for
Global Sepsis Alliance

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2022

	Page
Report of the Trustees	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9 to 10
Notes to the Financial Statements	11 to 16
Detailed Statement of Financial Activities	17 to 18

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2022

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporation governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate a range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring our work delivers our aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

The focus of our work

Our main objectives for the year 2022 continued to be those activities aimed at raising awareness and understanding of sepsis and its treatment, as well as igniting necessary policy changes and mental shifts in policymakers and governmental institutions, especially those involved in policymaking. These objectives are how we will actively pursue our vision:

A WORLD FREE OF SEPSIS

The strategies we used to meet these objectives included:

- working closely with the WHO and national governments towards having the World Health Assembly (WHA) adopt a resolution on sepsis. This was achieved in May 2017 at the 70th WHA, marking a quantum leap in the global fight against sepsis which was spearheaded by the GSA;
- working closely with the WHO and national governments to implement the demands of said WHA Resolution on Sepsis; especially fostering national sepsis strategies, and the integration of sepsis in existing health strategies
- the instigation of the first World Sepsis Day in September 2012 which is now a recurring annual event involving more than 60 countries and more than 300 events
- working to get World Sepsis Day officially recognized as a World Health Day by the World Health Organization
- the instigation of the Global Sepsis Awards in 2015, which is now a recurring initiative to highlight sepsis related projects and achievements on a global level each year
- the establishment of World Sepsis Congress in 2016 and World Sepsis Congress Spotlight in 2017. These free online conferences make knowledge about sepsis accessible to all parts of the world
- In 2022, we hosted the 2022 WSC Spotlight, titled 'WSC Spotlight: Novel Therapeutic and Diagnostic Approaches for COVID-19 and Sepsis' in April of 2022. The 2022 WSC Spotlight had more than 10,000 registrations from more than 180 countries, 8 sessions, and more than 45 speakers, moderators, and panelists. All talks are available for free on YouTube and as a podcast.
- the development and continuous maintenance and updating of websites for World Sepsis Day (www.worldsepsisday.org), World Sepsis Congress (www.worldsepsiscongress.org), WSC Spotlight (www.wscspotlight.org), as well as the Global Sepsis Alliance (<http://www.globalsepsisalliance.org/>)
- the development and publication of the World Sepsis Declaration, which was recently updated with goals and targets for 2030 and serves as our North Star
- the development and publication of relevant and timely news posts on our WSD and GSA websites, an email newsletter, as well as the use of social media, especially Twitter, Instagram, and Facebook
- sharing stories of people impacted by sepsis on our website and on social media;
- growing the network of the GSA (over 110 members at the end of 2022)
- working towards applying international standards and guidelines, in close connection to the demands of the before-mentioned resolution
- working in partnership with other organizations and agencies to secure the widest range of initiatives and encouraging action on sepsis.

Global Sepsis Alliance

Report of the Trustees for the Year Ended 31 December 2022

Briefly mentioned above, of specific significance in 2022 was the '2022 World Sepsis Congress Spotlight' - over the course of one day and 8 diverse and highly relevant sessions, over 45 speakers, panelists, and moderators from more than 30 countries gave trenchant talks on all the newest therapeutic and diagnostic approaches for COVID-19 and sepsis, covering all novel aspects of our understanding of bacterial and viral sepsis, from new methods of diagnosis and risk assessment to novel treatment modalities, and beyond. The congress took place entirely online and participation was free of charge, allowing participants to join from wherever they had an internet connection. The congress was a sweeping success, with more than 10,000 registrations from more than 180 countries. 65% of our audience joined from low- and middle-income countries (LMIC) - the majority of whom could not have afforded to travel to a physical congress to learn about sepsis. All presentations were recorded and continue to be available on our YouTube channel and on Apple Podcasts, easily accessible and free of charge. We plan to host the 4th World Sepsis Congress in 2023, and the 2024 WSC Spotlight in 2024.

Thanks to COVID, the GSA Awards were presented in a virtual ceremony this year. Throughout the year, the GSA also supported and promoted other health days with a relationship to sepsis, such as World Hand Hygiene Day and World Patient Safety Day. In early 2022, the GSA supported the IMC White Paper, which proposes a holistic infection management roadmap integrating AMR and sepsis.

The GSA also kept on supporting and growing its regional sepsis alliances - including their events, such as webinars and physical meetings. September also saw a big celebratory #10YearsWSD-Event in Berlin, as well as the 5th Annual Meeting of the European Sepsis Alliance in Brussels, featuring Stella Kyriakides, the European Commissioner for Health and Food Safety.

Gearing up for World Sepsis Day, we launched a new interactive world map, as well as a new interactive virtual photo booth - a super fun and engaging way to participate in WSD online.

Over the year, we also released new material on sepsis, such as updated infographics, as well as translated our existing sepsis awareness material to more languages.

How our activities deliver public benefit

Our main activities and who we try to help are described below. All our charitable activities focus on raising awareness and understanding of sepsis and its treatment and this remains our key challenge. All our activities are undertaken to further our charitable purposes for the public benefit.

Despite advances in modern medicine, including vaccines, antibiotics, and intensive care, sepsis remains the primary cause of death from infection, including viral infections such as COVID-19. Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly. Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What examples exist of who has benefited?

In 2012, the Ropy Staunton Foundation and Global Sepsis Alliance announced that they will unite to fight against sepsis, claims 17 deaths per minute, 24,480 deaths every day and 8-9 million lives annually. Our collaboration has continued into 2021 to create global sepsis awareness and mandates. 12-year-old Ropy scratched his elbow playing school basketball on March 29th, 2012. He soon became unwell and, having previously been sent home from a leading New York hospital, died four days later from unrecognized sepsis.

We formed a Communications Committee under the leadership of Dr Ron Daniels. This Committee was formed to recognize that public awareness is created through action and communication. The Committee will help to further develop ideas and our communications strategy to the press and social media over the whole year and especially around World Sepsis Day. Our efforts on social media are going well, with double-digit growth on Twitter, Facebook, and Instagram.

Global Sepsis Alliance

Report of the Trustees for the Year Ended 31 December 2022

The GSA also has a Quality Improvement Committee (QIC), focusing on research and quality improvement. That includes better protocols in hospitals to detect sepsis earlier, when it is easier to treat and manage.

PLANS FOR FUTURE PERIODS

The charity plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements. We plan to host another the 4th World Sepsis Congress in April 2023, as well as the 2024 WSC Spotlight in 2024. All other projects, for example WSD and the GSA Awards, will be continued in 2022.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2022

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr. Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr. Philip Taylor

Independent Examiner

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Executive Committee

Abdulelah Alhawsawi
Brett Abbenbroek
Daniela Souza
Dennis Kredler
Emmanuel Nsutebu
Imrana Malik
Maha Aljuaid
Niranjan 'Tex' Kissoon
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Antonio Artigas, Brett Abbenbroek, Daniela Souza, Dennis Kredler, Emmanuel Nsutebu, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Louise Thwaites, Luis Antonio Gorordo Del Sol, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Niranjan 'Tex' Kissoon, Ron Daniels, Shevin Jacob, Tobias Welte, Ulrika Knutsson

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2022

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr. Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Sanjay Swarup

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2022

		2022 Unrestricted fund £	2021 Total funds £
	Notes		
INCOME AND ENDOWMENTS FROM			
Donations and legacies	2	198,833	211,550
Other trading activities	3	55,277	131,553
Total		<u>254,110</u>	<u>343,103</u>
 EXPENDITURE ON			
Raising funds	4	373,060	209,276
		<u> </u>	<u> </u>
NET INCOME/(EXPENDITURE)		(118,950)	133,827
 RECONCILIATION OF FUNDS			
Total funds brought forward		749,485	615,658
		<u> </u>	<u> </u>
TOTAL FUNDS CARRIED FORWARD		<u><u>630,535</u></u>	<u><u>749,485</u></u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2022

		2022 Unrestricted fund £	2021 Total funds £
	Notes		
FIXED ASSETS			
Tangible assets	9	10,162	8,858
CURRENT ASSETS			
Debtors	10	79,706	89,936
Cash at bank		548,561	655,593
		<u>628,267</u>	<u>745,529</u>
CREDITORS			
Amounts falling due within one year	11	(7,894)	(4,902)
NET CURRENT ASSETS		<u>620,373</u>	<u>740,627</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		630,535	749,485
NET ASSETS		<u>630,535</u>	<u>749,485</u>
FUNDS	12		
Unrestricted funds		<u>630,535</u>	<u>749,485</u>
TOTAL FUNDS		<u>630,535</u>	<u>749,485</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

Global Sepsis Alliance

Balance Sheet - continued

31 December 2022

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:

.....
Mr. Philip Taylor - Trustee

Notes to the Financial Statements
for the Year Ended 31 December 2022

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. DONATIONS AND LEGACIES

	2022	2021
	£	£
Donations	<u>198,833</u>	<u>211,550</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

3. OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Sponsorships	55,277	131,553

4. RAISING FUNDS

RAISING DONATIONS AND LEGACIES

	2022	2021
	£	£
Postage and stationery	1,841	2,747
Other direct cost	3,646	16,953
Travel subsistence & accommodation	3,179	2,434
Event costs	96,594	55,479
Support costs	267,800	131,663
	373,060	209,276

5. SUPPORT COSTS

	Management	Finance	Information technology
	£	£	£
Raising donations and legacies	231,495	448	5,806
		Governance	
	Other	costs	Totals
	£	£	£
Raising donations and legacies	3,388	24,440	267,800

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022	2021
	£	£
Depreciation - owned assets	3,388	7,136

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

8. STAFF COSTS

	2022 £	2021 £
Wages and salaries	168,656	125,747
	<u>168,656</u>	<u>125,747</u>

The average monthly number of employees during the year was as follows:

	2022	2021
Employees	8	8
	<u>8</u>	<u>8</u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery £	Fixtures and fittings £	Computer equipment £	Totals £
COST				
At 1 January 2022	838	8,172	15,105	24,115
Additions	-	-	4,692	4,692
	<u>838</u>	<u>8,172</u>	<u>19,797</u>	<u>28,807</u>
At 31 December 2022	838	8,172	19,797	28,807
DEPRECIATION				
At 1 January 2022	419	5,091	9,747	15,257
Charge for year	105	770	2,513	3,388
	<u>524</u>	<u>5,861</u>	<u>12,260</u>	<u>18,645</u>
At 31 December 2022	524	5,861	12,260	18,645
NET BOOK VALUE				
At 31 December 2022	314	2,311	7,537	10,162
At 31 December 2021	419	3,081	5,358	8,858

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Trade debtors	60,398	70,836
Investment	18,639	18,639
VAT	669	461
	<u>79,706</u>	<u>89,936</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Social security and other taxes	6,209	3,342
Accrued expenses	1,685	1,560
	<u>7,894</u>	<u>4,902</u>

12. MOVEMENT IN FUNDS

	At 1.1.22	Net movement in funds	At 31.12.22
	£	£	£
Unrestricted funds			
General fund	749,485	(118,950)	630,535
	<u>749,485</u>	<u>(118,950)</u>	<u>630,535</u>
TOTAL FUNDS	<u>749,485</u>	<u>(118,950)</u>	<u>630,535</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	254,110	(373,060)	(118,950)
	<u>254,110</u>	<u>(373,060)</u>	<u>(118,950)</u>
TOTAL FUNDS	<u>254,110</u>	<u>(373,060)</u>	<u>(118,950)</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	615,658	133,827	749,485
TOTAL FUNDS	<u>615,658</u>	<u>133,827</u>	<u>749,485</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	343,103	(209,276)	133,827
TOTAL FUNDS	<u>343,103</u>	<u>(209,276)</u>	<u>133,827</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.21 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	615,658	14,877	630,535
TOTAL FUNDS	<u>615,658</u>	<u>14,877</u>	<u>630,535</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	597,213	(582,336)	14,877
TOTAL FUNDS	<u>597,213</u>	<u>(582,336)</u>	<u>14,877</u>

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,000 (PY - £2,525). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2022

	2022 £	2021 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	198,833	211,550
Other trading activities		
Sponsorships	55,277	131,553
Total incoming resources	254,110	343,103
EXPENDITURE		
Raising donations and legacies		
Postage and stationery	1,841	2,747
Other direct cost	3,646	16,953
Travel subsistence & accommodation	3,179	2,434
Event costs	96,594	55,479
	105,260	77,613
Support costs		
Management		
Wages	168,656	125,747
Computer Cost	5,785	(4,790)
Insurance	39,276	(40,162)
Office Rent	9,987	6,585
Staff welfare	79	322
Telephone	859	852
Advertising	5,146	6,885
Office cost	266	158
Bookkeeping	768	918
Consultancy	2,000	2,345
Foreign Exchange Loss	(1,327)	7,157
	231,495	106,017
Finance		
Bank charges	336	366
Paypal charges	112	207
	448	573
Information technology		
Website development	5,806	4,566

This page does not form part of the statutory financial statements

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2022

	2022 £	2021 £
Information technology		
Other		
Plant and machinery	105	139
Fixtures and fittings	770	1,027
Computer equipment	2,513	5,970
	3,388	7,136
 Other 2		
Subscription	2,223	689
 Governance costs		
Membership fees	19,755	8,597
Accountancy fees	1,685	1,560
Secretary	3,000	2,525
	24,440	12,682
 Total resources expended	373,060	209,276
 Net (expenditure)/income	 (118,950)	 133,827

This page does not form part of the statutory financial statements

Accounts

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31 December 2021
for
Global Sepsis Alliance

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2021

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance Sheet	8
Notes to the Financial Statements	9 to 13
Detailed Statement of Financial Activities	14 to 15

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2021

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporation governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate a range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring our work delivers our aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review looks at what we achieved and the outcomes of our work in the previous 12 months. The review looks at the success of each key activity and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees and Executive Board jointly consider how planned activities will contribute to the aims and objectives they have set.

The focus of our work

Our main objectives for the year 2021 continued to be those activities aimed at raising awareness and understanding of sepsis and its treatment, as well as igniting necessary policy changes and mental shifts in policy makers and governmental institutions, especially those involved in policymaking. These objectives are how we will actively pursue our vision:

A WORLD FREE OF SEPSIS

The strategies we used to meet these objectives included:

- working closely with the WHO and national governments toward having the World Health Assembly (WHA) adopt a resolution on sepsis, which happened in May 2017 at the 70th WHA, marking a quantum leap in the global fight against sepsis, spearheaded by the GSA;
- working closely with the WHO and national governments to implement the demands of said WHA Resolution on Sepsis; especially fostering national sepsis strategies, and the integration of sepsis in existing health strategies
- the instigation of the first World Sepsis Day in September 2012 which is now a recurring annual event involving more than 60 countries and more than 300 events
- working to get World Sepsis Day officially recognized as a World Health Day by the World Health Organization
- the instigation of the Global Sepsis Awards in 2015, which is now a recurring initiative to highlight sepsis related projects and achievements on a global level each year
- the establishment of World Sepsis Congress in 2016 and World Sepsis Congress Spotlight in 2017. These free online conferences deliver knowledge about sepsis to all parts of the world; and we hosted the World Sepsis Congress 2021 in 2021
- the development of websites for World Sepsis Day (www.worldsepsisday.org), World Sepsis Congress (www.worldsepsiscongress.org), WSC Spotlight (www.wscspotlight.org), as well as the Global Sepsis Alliance (www.global-sepsis-alliance.org)
- the development and publication of the World Sepsis Declaration, which was recently updated with goals and targets for 2030 and serves as our North Star
- the development and publication of relevant and timely news posts on our WSD and GSA websites, an email newsletter, as well as the use of social media, especially Twitter, Instagram, and Facebook
- sharing stories of people impacted by sepsis on our website and on social media;
- growing the network of the GSA (over 110 members at the end of 2021)
- working towards applying international standards and guidelines, in close connection to the demands of the before-mentioned resolution
- working in partnership with other organizations and agencies to secure the widest range of initiatives and encouraging action on sepsis.

Global Sepsis Alliance

Report of the Trustees for the Year Ended 31 December 2021

Of specific significance in 2021 was the 'World Sepsis Congress 2021' - over the course of two days and 15 diverse and highly relevant sessions, over 90 speakers from more than 30 countries gave trenchant talks on all aspects of sepsis, from the impact of policy, the role of artificial intelligence and big data, patient safety, and long-term sequelae through to novel trial design, the latest research, and much more. The congress took place entirely online and participation was free of charge, allowing participants to join from wherever they had an internet connection. The congress was a sweeping success, with more than 19,000 registrations from 181 countries. 71% of our audience joined from low- and middle-income countries (LMIC) - the majority of whom could not have afforded to travel to a physical congress to learn about sepsis. All presentations were recorded and continue to be available on our YouTube channel and on Apple Podcasts, easily accessible and free of charge. We plan to host a WSC Spotlight in 2022 and the 4th World Sepsis Congress in 2023.

Thanks to COVID, the GSA Awards were presented in a virtual ceremony this year. Throughout the year, the GSA also supported and promoted other health days with a relationship to sepsis, such as World Hand Hygiene Day and World Patient Safety Day. Jointly with ESICM and SCCM, we published a consensus paper in Intensive Care Medicine, emphasizing the importance of recognizing that patients critically ill with COVID-19 have viral sepsis, despite some differences from sepsis caused by other pathogens.

The GSA also kept on supporting and growing its regional sepsis alliances - in 2021, we unveiled the new logo and website for the Eastern Mediterranean Sepsis Alliance (EMSA), and EMSA also hosted a free webinar in September. September also saw the 4th Annual Meeting of the European Sepsis Alliance, and the launch of our new World Sepsis Day Quiz - a fun and interactive way to test your knowledge about sepsis.

Over the year, we also released new material on sepsis, such as a updated infographics, as well as translated our existing sepsis awareness material to more languages.

How our activities deliver public benefit

Our main activities and who we try to help are described below. All our charitable activities focus on raising awareness and understanding of sepsis and its treatment and this remains our key challenge. All our activities are undertaken to further our charitable purposes for the public benefit.

Despite advances in modern medicine, including vaccines, antibiotics, and intensive care, sepsis remains the primary cause of death from infection, including viral infections such as COVID-19. Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly. Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What examples exist of who has benefited?

In 2012, the Rory Staunton Foundation and Global Sepsis Alliance announced that they will unite to fight against sepsis, claims 17 deaths per minute, 24,480 deaths every day and 8-9 million lives annually. Our collaboration has continued into 2021 to create global sepsis awareness and mandates. 12-year-old Rory scratched his elbow playing school basketball on March 29th, 2012. He soon became unwell and, having previously been sent home from a leading New York hospital, died four days later from unrecognized sepsis.

We formed a Communications Committee under the leadership of Dr Ron Daniels. This Committee was formed to recognize that public awareness is created through action and communication. The Committee will help to further develop ideas and our communications strategy to the press and social media over the whole year and especially around World Sepsis Day. Our efforts on social media are going well, with double-digit growth on Twitter, Facebook, and Instagram.

The GSA also has a Quality Improvement Committee (QIC), focusing on research and quality improvement. That includes better protocols in hospitals to detect sepsis earlier, when it is easier to treat and manage.

PLANS FOR FUTURE PERIODS

The charity plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements. We plan to host another WSC Spotlight in April 2022, as well as the 4th WSC in 2023. All other projects, for example WSD and the GSA Awards, will be continued in 2021.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr. Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr. Philip Taylor

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2021

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Executive Committee

Abdulelah Alhawsawi
Brett Abbenbroek
Daniela Souza
Dennis Kredler
Emmanuel Nsutebu
Imrana Malik
Maha Aljuaid
Niranjan 'Tex' Kissoon
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Antonio Artigas, Brett Abbenbroek, Daniela Souza, Dennis Kredler, Emmanuel Nsutebu, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Louise Thwaites, Luis Antonio Gorordo Del Sol, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Niranjan 'Tex' Kissoon, Ron Daniels, Shevin Jacob, Tobias Welte, Ulrika Knutsson

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr. Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Sanjay Swarup
ICAEW
Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2021

	Notes	2021 Unrestricted fund £	2020 Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	2	211,550	102,563
Other trading activities	3	131,553	164,909
Total		<u>343,103</u>	<u>267,472</u>
 EXPENDITURE ON			
Raising funds	4	209,276	249,532
NET INCOME		133,827	17,940
 RECONCILIATION OF FUNDS			
Total funds brought forward		615,658	597,718
 TOTAL FUNDS CARRIED FORWARD		<u><u>749,485</u></u>	<u><u>615,658</u></u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2021

	Notes	2021 Unrestricted fund £	2020 Total funds £
FIXED ASSETS			
Tangible assets	9	8,858	6,078
CURRENT ASSETS			
Debtors	10	89,936	32,227
Cash at bank		655,593	658,791
		745,529	691,018
CREDITORS			
Amounts falling due within one year	11	(4,902)	(81,438)
NET CURRENT ASSETS		740,627	609,580
TOTAL ASSETS LESS CURRENT LIABILITIES			
		749,485	615,658
NET ASSETS			
		749,485	615,658
FUNDS	12		
Unrestricted funds		749,485	615,658
TOTAL FUNDS		749,485	615,658

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:

.....
Mr. Philip Taylor - Trustee

The notes form part of these financial statements

Notes to the Financial Statements
for the Year Ended 31 December 2021

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. DONATIONS AND LEGACIES

	2021	2020
	£	£
Donations	<u>211,550</u>	<u>102,563</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

3. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Sponsorships	<u>131,553</u>	<u>164,909</u>

4. RAISING FUNDS**RAISING DONATIONS AND LEGACIES**

	2021	2020
	£	£
Postage and stationery	2,747	3,714
Other direct cost	16,953	2,910
Travel subsistence & accommodation	2,434	5,628
Event costs	55,479	29,107
Support costs	<u>131,663</u>	<u>208,173</u>
	<u>209,276</u>	<u>249,532</u>

5. SUPPORT COSTS

	Management £	Finance £	Information technology £
Raising donations and legacies	<u>146,179</u>	<u>(39,589)</u>	<u>4,566</u>
	Other £	Governance costs £	Totals £
Raising donations and legacies	<u>7,136</u>	<u>689</u>	<u>12,682</u>
			<u>131,663</u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2021	2020
	£	£
Depreciation - owned assets	<u>7,136</u>	<u>2,026</u>

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

8. STAFF COSTS

	2021 £	2020 £
Wages and salaries	125,747	126,145
	<u>125,747</u>	<u>126,145</u>

The average monthly number of employees during the year was as follows:

	2021	2020
Employees	8	7
	<u>8</u>	<u>7</u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery £	Fixtures and fittings £	Computer equipment £	Totals £
COST				
At 1 January 2021	1,224	5,855	7,120	14,199
Additions	-	-	9,916	9,916
Reclassification	(386)	2,317	(1,931)	-
	<u>838</u>	<u>8,172</u>	<u>15,105</u>	<u>24,115</u>
At 31 December 2021	838	8,172	15,105	24,115
DEPRECIATION				
At 1 January 2021	449	2,508	5,164	8,121
Charge for year	139	1,027	5,970	7,136
Reclassification/transfer	(169)	1,556	(1,387)	-
	<u>419</u>	<u>5,091</u>	<u>9,747</u>	<u>15,257</u>
At 31 December 2021	419	5,091	9,747	15,257
NET BOOK VALUE				
At 31 December 2021	<u>419</u>	<u>3,081</u>	<u>5,358</u>	<u>8,858</u>
At 31 December 2020	<u>775</u>	<u>3,347</u>	<u>1,956</u>	<u>6,078</u>

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Trade debtors	70,836	13,390
Investment	18,639	18,639
VAT	461	198
	<u>89,936</u>	<u>32,227</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Social security and other taxes	3,342	79,958
Accrued expenses	1,560	1,480
	<u>4,902</u>	<u>81,438</u>

12. MOVEMENT IN FUNDS

	At 1.1.21	Net movement in funds	At 31.12.21
	£	£	£
Unrestricted funds			
General fund	615,658	133,827	749,485
	<u>615,658</u>	<u>133,827</u>	<u>749,485</u>
TOTAL FUNDS	<u>615,658</u>	<u>133,827</u>	<u>749,485</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	343,103	(209,276)	133,827
	<u>343,103</u>	<u>(209,276)</u>	<u>133,827</u>
TOTAL FUNDS	<u>343,103</u>	<u>(209,276)</u>	<u>133,827</u>

Comparatives for movement in funds

	At 1.1.20	Net movement in funds	At 31.12.20
	£	£	£
Unrestricted funds			
General fund	597,718	17,940	615,658
	<u>597,718</u>	<u>17,940</u>	<u>615,658</u>
TOTAL FUNDS	<u>597,718</u>	<u>17,940</u>	<u>615,658</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	267,472	(249,532)	17,940
	<u>267,472</u>	<u>(249,532)</u>	<u>17,940</u>
TOTAL FUNDS	<u>267,472</u>	<u>(249,532)</u>	<u>17,940</u>

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.20 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	597,718	151,767	749,485
TOTAL FUNDS	<u>597,718</u>	<u>151,767</u>	<u>749,485</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	610,575	(458,808)	151,767
TOTAL FUNDS	<u>610,575</u>	<u>(458,808)</u>	<u>151,767</u>

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £2,525 (PY - £2,607). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2021

	2021 £	2020 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	211,550	102,563
Other trading activities		
Sponsorships	131,553	164,909
Total incoming resources	343,103	267,472
EXPENDITURE		
Raising donations and legacies		
Postage and stationery	2,747	3,714
Other direct cost	16,953	2,910
Travel subsistence & accommodation	2,434	5,628
Event costs	55,479	29,107
	77,613	41,359
Support costs		
Management		
Wages	125,747	126,145
Computer Cost	(4,790)	7,456
Office Rent	6,585	-
Staff welfare	322	1,132
Telephone	852	-
Advertising	6,885	15,073
Office cost	158	-
Bookkeeping	918	975
Consultancy	2,345	-
Foreign Exchange Loss	7,157	(9,780)
	146,179	141,001
Finance		
Insurance	(40,162)	48,748
Bank charges	366	325
Paypal charges	207	551
	(39,589)	49,624
Information technology		
Website development	4,566	3,889
Other		
Plant and machinery	139	258
Fixtures and fittings	1,027	1,116
Computer equipment	5,970	652
	7,136	2,026

This page does not form part of the statutory financial statements

Global Sepsis Alliance


Detailed Statement of Financial Activities
for the Year Ended 31 December 2021

	2021 £	2020 £
Other		
Other 2		
Subscription	689	500
Governance costs		
Membership fees	8,597	-
Accountancy and legal fees	1,560	1,480
Secretary	2,525	2,607
Legal fees	-	7,046
	12,682	11,133
Total resources expended	209,276	249,532
Net income	133,827	17,940


Accounts

REGISTERED COMPANY NUMBER: 07476120 (England and Wales)
REGISTERED CHARITY NUMBER: 1142803

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31 December 2020
for
Global Sepsis Alliance



Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL



Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2020

	Page
Report of the Trustees	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9 to 10
Notes to the Financial Statements	11 to 16
Detailed Statement of Financial Activities	17 to 18

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2020

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2020

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate a range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring our work delivers our aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review looks at what we achieved and the outcomes of our work in the previous 12 months. The review looks at the success of each key activity and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees and Executive Board jointly consider how planned activities will contribute to the aims and objectives they have set.

The focus of our work

Our main objectives for the year 2020 continued to be those activities aimed at raising awareness and understanding of sepsis and its treatment, as well as igniting necessary policy changes and mental shifts in policy makers and governmental institutions, especially those involved in policy-making. These objectives are how we will actively pursue our vision:

A WORLD FREE OF SEPSIS

The strategies we used to meet these objectives included:

- working closely with the WHO and national governments toward having the World Health Assembly (WHA) adopt a resolution on sepsis, which happened in May 2017 at the 70th WHA, marking a quantum leap in the global fight against sepsis, spearheaded by the GSA;
- working closely with the WHO and national governments to implement the demands of said WHA Resolution on Sepsis;
- the instigation of the first World Sepsis Day in September 2012 and now a recurring annual event involving more than 60 countries and more than 250 events;
- working to get World Sepsis Day officially recognized as a World Health Day by the World Health Assembly;
- the instigation of the Global Sepsis Awards in 2015, now a recurring initiative highlighting sepsis related projects and achievements on a global level each year;
- the establishment of World Sepsis Congress in 2016 and World Sepsis Congress Spotlight in 2017, both free online conferences bringing knowledge about sepsis to all parts of the world;
- the development of websites for World Sepsis Day (www.worldsepsisday.org), World Sepsis Congress (www.worldsepsiscongress.org), WSC Spotlight (www.wscspotlight.org), as well as the Global Sepsis Alliance (www.global-sepsis-alliance.org);
- the development and publication of the World Sepsis Declaration;
- the development and publication of relevant and timely news posts on our WSD and GSA websites, an email newsletter, as well as the use of social media, especially Twitter, Instagram, and Facebook;
- sharing stories of people impacted by sepsis on our website and on social media;
- growing the network of the GSA (over 90 members at the end of 2019);
- working towards applying international standards and guidelines, in close connection to the demands of the resolution;
- working in partnership with other organizations and agencies to secure the widest range of initiatives and encouraging action on sepsis.

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2020

Of specific significance in 2020 was the "WSC Spotlight: Sepsis, Pandemics, and Antimicrobial Resistance - Global Health Threats of the 21st Century", which was hosted jointly with the World Health Organization as a free online congress on September 9, 2020. Over the course of one day and six sessions, the WSC Spotlight brought together more than 30 renowned experts from 20 countries. Over 10,000 people from more than 180 countries signed up to participate, of which over half (58%) were from low- and middle-income countries (LMIC) - the majority of whom could not have afforded to travel to a physical congress to learn about sepsis. All presentations were recorded and continue to be available on our YouTube channel and on Apple Podcasts, easily accessible and free of charge. We plan to host the 3rd World Sepsis Congress in 2021 and the next WSC Spotlight in 2022.

Another significant development in 2020 was the publication of new research on sepsis. In January 2020, an international team of scientists published a groundbreaking study in The Lancet. This study, the most comprehensive clinical study on sepsis to date, revealed at least 48.9 million cases of sepsis in 2017 and 11 million deaths. 1 in 5 deaths globally are associated with sepsis.

A key study finding was that 85% of sepsis cases occurred in low- or middle-income countries - especially in Sub-Saharan Africa, the South Pacific islands, and South, East, and Southeast Asia. While sepsis incidence is higher among females than males, more than 40% of all cases are occurring in children under 5. This research is tremendously helpful for our cause, since previously available data was only extrapolated and thus a huge underestimate. That said, the current data might still be an underestimate. Of the 23 authors that contributed to this paper, 4 are members of the Executive Committee of the Global Sepsis Alliance.

Also in January of 2020, we overhauled and updated our World Sepsis Declaration - publishing a new version setting our goals for 2030. The declaration continues to be our north star, together with the resolution on sepsis.

Later in the year, we launched our new online shop - featuring World Sepsis Day merchandise such as t-shirts, hoodies, stickers, balloons, bags, and much more. The store is an affordable way for our supporters to improve their WSD events and campaigns and has the potential to be a small source of income for the GSA in a couple of years.

Over the year, we also released new material on sepsis, such as a new fact sheet, as well as translated our existing sepsis awareness material to more languages. We also updated our video explaining sepsis in 3 minutes to include COVID, the new numbers on sepsis, as well as more languages.

How our activities deliver public benefit

Our main activities and who we try to help are described below. All our charitable activities focus on raising awareness and understanding of sepsis and its treatment and this remains our key challenge. All our activities are undertaken to further our charitable purposes for the public benefit.

Despite advances in modern medicine, including vaccines, antibiotics, and intensive care, sepsis remains the primary cause of death from infection, including viral infections such as COVID-19. Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly. Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What examples exist of who has benefited?

In 2012, the Rory Staunton Foundation and Global Sepsis Alliance announced that they will unite to fight against sepsis, claims 17 deaths per minute, 24,480 deaths every day and 8-9 million lives annually. Our collaboration has continued into 2020 to create global sepsis awareness and mandates. 12-year-old Rory scratched his elbow playing school basketball on March 29th, 2012. He soon became unwell and, having previously been sent home from a leading New York hospital, died four days later from unrecognized sepsis.

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2020

We formed a Communications Committee under the leadership of Dr Ron Daniels. This Committee was formed to recognize that public awareness is created through action and communication. The Committee will help to further develop ideas and our communications strategy to the press and social media over the whole year and especially around World Sepsis Day. Our efforts on social media are going well, with double-digit growth on Twitter, Facebook, and Instagram.

The GSA also has a Quality Improvement Committee (QIC), focusing on research and quality improvement. That includes better protocols in hospitals to detect sepsis earlier, when it is easier to treat and manage.

PLANS FOR FUTURE PERIODS

The charity plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements. We plan to host another WSC in April 2021, as well as another WSC Spotlight in 2022. All other projects, for example WSD, the GSA Awards, will be continued in 2020.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Board who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Board give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2020

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr. Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Daniels Director

Company Secretary

Mr. Philip Taylor

Independent Examiner

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Executive Board

Prof K A Reinhart	Chairman
Dr D Daniels	CEO
N Kissoon	Vice Chairman
F Machado	Secretary
S Finfer	Treasurer
R Schachter	Governance

Council Members

Derek Angus; Andrew Argent; Antonio Artigas; Bin Du; Simon Finfer; Tex Kissoon; Mitchell Levy; Flávia R. Machado; John Marshall; Jean-Paul Mira; Satoshi Nakagawa; Hussain Nasser Al Rahma; Jim O'Brien; E. Papathanassoglou; Kevin Tracey; Kevin Rooney.

24 September 2021

Approved by order of the board of trustees on and signed on its behalf by:

Global Sepsis Alliance

Report of the Trustees
for the Year Ended 31 December 2020

DocuSigned by:

Philip Taylor

FFB2917E9C8A44F.....

Mr. Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2020.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Sanjay Swarup
ICAEW
Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis AllianceStatement of Financial Activities
for the Year Ended 31 December 2020

		2020 Unrestricted fund £	2019 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies	2	102,563	21,566
Other trading activities	3	164,909	216,700
Total		<u>267,472</u>	<u>238,266</u>
EXPENDITURE ON			
Raising funds	4	249,532	127,593
Other		-	94,422
Total		<u>249,532</u>	<u>222,015</u>
NET INCOME		<u>17,940</u>	<u>16,251</u>
RECONCILIATION OF FUNDS			
Total funds brought forward		<u>597,718</u>	<u>581,467</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>615,658</u></u>	<u><u>597,718</u></u>

Global Sepsis AllianceBalance Sheet
31 December 2020

	Notes	2020 Unrestricted fund £	2019 Total funds £
FIXED ASSETS			
Tangible assets	9	6,078	7,356
CURRENT ASSETS			
Debtors	10	32,227	18,744
Cash at bank		658,791	628,787
		<u>691,018</u>	<u>647,531</u>
CREDITORS			
Amounts falling due within one year	11	(81,438)	(57,169)
NET CURRENT ASSETS		<u>609,580</u>	<u>590,362</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		615,658	597,718
NET ASSETS		<u>615,658</u>	<u>597,718</u>
FUNDS	12		
Unrestricted funds		615,658	597,718
TOTAL FUNDS		<u>615,658</u>	<u>597,718</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


Global Sepsis Alliance

Balance Sheet - continued
31 December 2020

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

24 September 2021

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

DocuSigned by:

EF820172BC8244F.....
Mr. Philip Taylor - Trustee

Global Sepsis Alliance

Notes to the Financial Statements
for the Year Ended 31 December 2020

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

HIRE PURCHASE AND LEASING COMMITMENTS

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Global Sepsis AllianceNotes to the Financial Statements - continued
for the Year Ended 31 December 2020**2. DONATIONS AND LEGACIES**

	2020	2019
	£	£
Donations	<u>102,563</u>	<u>21,566</u>

3. OTHER TRADING ACTIVITIES

	2020	2019
	£	£
Sponsorships	<u>164,909</u>	<u>216,700</u>

4. RAISING FUNDS**RAISING DONATIONS AND LEGACIES**

	2020	2019
	£	£
Postage and stationery	3,714	1,253
Other direct cost	2,910	-
Travel & accommodation	5,628	11,441
Event costs	29,107	19,933
Support costs	<u>208,173</u>	<u>-</u>
	<u>249,532</u>	<u>32,627</u>

OTHER TRADING ACTIVITIES

	2020	2019
	£	£
Support costs	<u>-</u>	<u>94,966</u>
Aggregate amounts	<u>249,532</u>	<u>127,593</u>

5. SUPPORT COSTS

	Management	Finance	Information technology
	£	£	£
Raising donations and legacies	<u>189,749</u>	<u>876</u>	<u>3,889</u>

Global Sepsis AllianceNotes to the Financial Statements - continued
for the Year Ended 31 December 2020**5. SUPPORT COSTS - continued**

	Other £	Other 2 £	Governance costs £	Totals £
Raising donations and legacies	<u>2,026</u>	<u>500</u>	<u>11,133</u>	<u>208,173</u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2020 £	2019 £
Depreciation - owned assets	2,026	2,453
Other operating leases	<u>48,748</u>	<u>38,001</u>

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2020 nor for the year ended 31 December 2019.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2020 nor for the year ended 31 December 2019.

8. STAFF COSTS

	2020 £	2019 £
Wages and salaries	<u>126,145</u>	<u>94,966</u>
	<u>126,145</u>	<u>94,966</u>

The average monthly number of employees during the year was as follows:

	2020	2019
Employees	<u>7</u>	<u>9</u>

No employees received emoluments in excess of £60,000.

Global Sepsis AllianceNotes to the Financial Statements - continued
for the Year Ended 31 December 2020**9. TANGIBLE FIXED ASSETS**

	Plant and machinery £	Fixtures and fittings £	Computer equipment £	Totals £
COST				
At 1 January 2020	765	5,566	7,120	13,451
Additions	459	289	-	748
	<u>1,224</u>	<u>5,855</u>	<u>7,120</u>	<u>14,199</u>
At 31 December 2020				
DEPRECIATION				
At 1 January 2020	191	1,392	4,512	6,095
Charge for year	258	1,116	652	2,026
	<u>449</u>	<u>2,508</u>	<u>5,164</u>	<u>8,121</u>
At 31 December 2020				
NET BOOK VALUE				
At 31 December 2020	<u>775</u>	<u>3,347</u>	<u>1,956</u>	<u>6,078</u>
At 31 December 2019	<u>574</u>	<u>4,174</u>	<u>2,608</u>	<u>7,356</u>

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Trade debtors	13,390	-
Investment	18,639	18,639
VAT	198	105
	<u>32,227</u>	<u>18,744</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020 £	2019 £
Social security and other taxes	79,958	55,734
Accrued expenses	1,480	1,435
	<u>81,438</u>	<u>57,169</u>

Global Sepsis AllianceNotes to the Financial Statements - continued
for the Year Ended 31 December 2020**12. MOVEMENT IN FUNDS**

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	597,718	17,940	615,658
TOTAL FUNDS	<u>597,718</u>	<u>17,940</u>	<u>615,658</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	267,472	(249,532)	17,940
TOTAL FUNDS	<u>267,472</u>	<u>(249,532)</u>	<u>17,940</u>

Comparatives for movement in funds

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	581,467	16,251	597,718
TOTAL FUNDS	<u>581,467</u>	<u>16,251</u>	<u>597,718</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	238,266	(222,015)	16,251
TOTAL FUNDS	<u>238,266</u>	<u>(222,015)</u>	<u>16,251</u>

Global Sepsis AllianceNotes to the Financial Statements - continued
for the Year Ended 31 December 2020**12. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.19 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	581,467	34,191	615,658
TOTAL FUNDS	<u>581,467</u>	<u>34,191</u>	<u>615,658</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	505,738	(471,547)	34,191
TOTAL FUNDS	<u>505,738</u>	<u>(471,547)</u>	<u>34,191</u>

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £2,607 (PY - £3,284). Mr. Philip Taylor is common director in both company. There was no balance outstanding for these services as at 31 December 2020.

Global Sepsis AllianceDetailed Statement of Financial Activities
for the Year Ended 31 December 2020

	2020 £	2019 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	102,563	21,566
Other trading activities		
Sponsorships	164,909	216,700
Total incoming resources	267,472	238,266
EXPENDITURE		
Raising donations and legacies		
Postage and stationery	3,714	1,253
Other direct cost	2,910	-
Travel & accommodation	5,628	11,441
Event costs	29,107	19,933
	41,359	32,627
Support costs		
Management		
Wages	126,145	94,966
Insurance	48,748	38,001
Computer Cost	7,456	11,225
Staff welfare	1,132	-
Advertising	15,073	9,746
Office Rent	-	2,434
Bookkeeping	975	854
Light and heat	-	289
Foreign Exchange Loss	(9,780)	9,755
	189,749	167,270
Finance		
Bank charges	325	245
Paypal charges	551	-
Merchant charges	-	135
	876	380
Information technology		
Website development	3,889	3,050
Other		
Plant and machinery	258	191
Carried forward	258	191

Global Sepsis AllianceDetailed Statement of Financial Activities
for the Year Ended 31 December 2020

	2020 £	2019 £
Other		
Brought forward	258	191
Fixtures and fittings	1,116	1,392
Computer equipment	652	870
	<u>2,026</u>	<u>2,453</u>
Other 2		
Subscription	500	626
Governance costs		
Accountancy and legal fees	1,480	1,435
Secretary	2,607	3,284
Legal fees	7,046	10,890
	<u>11,133</u>	<u>15,609</u>
Total resources expended	<u>249,532</u>	<u>222,015</u>
Net income	<u><u>17,940</u></u>	<u><u>16,251</u></u>